An inventory of European data sources to support pharmacoepidemiologic research on neurodevelopmental outcomes in children following medication exposure in pregnancy: A contribution from the ConcePTION project

Background Studies on medication safety in pregnancy are increasingly focusing on child neurodevelopmental outcomes. Establishing neurodevelopmental safety is complex due to the range of neurodevelopmental outcomes and the length of follow-up needed for accurate assessment. The aim of this study was to provide an inventory of European data sources for use in pharmacoepidemiologic studies investigating neurodevelopment following maternal medication exposure. Method The EUROmediSAFE inventory of data sources in Europe for evaluating perinatal and long-term childhood risks associated with in-utero exposure to medication was updated by contacting colleagues across 31 European countries, literature review and internet searches. Included data sources must record at least one neurodevelopmental outcome and maternal medication use in pregnancy must be available, either in the data source itself or through linkage with another data source. Information on the domain of neurodevelopment, measure/scale used and the approach to measurement were recorded for each data source. Results Ninety data sources were identified across 14 countries. The majority (63.3%) were created for health surveillance and research with the remaining serving administrative purposes (21.1% healthcare databases,15.6% other administrative databases). Five domains of neurodevelopment were identified—infant development (36 data sources,13 countries), child behaviour (27 data sources, 10 countries), cognition (29 data sources, 12 countries), educational achievement (20 data sources, 7 countries), and diagnostic codes for neurodevelopmental disorders (42 data sources, 11 countries). Thirty-nine data sources, in 12 countries, had information on more than one domain of neurodevelopment. Conclusion This inventory is invaluable to future studies planning to investigate the neurodevelopmental impact of medication exposures during pregnancy. Caution must be used when combining varied approaches to neurodevelopment outcome measurement, the age of children in the data source, and the sensitivity and specificity of the outcome measure selected should be borne in mind.

[1]  M. Loane,et al.  Linking a European cohort of children born with congenital anomalies to vital statistics and mortality records: A EUROlinkCAT study , 2021, PloS one.

[2]  F. Ramus,et al.  Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France , 2020, Scientific Reports.

[3]  Cassandra L. Hendrix,et al.  School-age social behavior and pragmatic language ability in children with prenatal serotonin reuptake inhibitor exposure , 2020, Development and Psychopathology.

[4]  R. Bromley,et al.  Use and validity of child neurodevelopment outcome measures in studies on prenatal exposure to psychotropic and analgesic medications – A systematic review , 2019, PloS one.

[5]  S. Dalsgaard,et al.  Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring , 2019, JAMA network open.

[6]  M. Mon-Williams,et al.  The association between socioeconomic status and autism diagnosis in the United Kingdom for children aged 5–8 years of age: Findings from the Born in Bradford cohort , 2019, Autism : the international journal of research and practice.

[7]  G. Collins,et al.  Handling time varying confounding in observational research , 2017, British Medical Journal.

[8]  P. Hardy,et al.  Risk for Autism Spectrum Disorders According to Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis , 2017, JAMA pediatrics.

[9]  E. Clementi,et al.  Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study , 2017, Therapeutic drug monitoring.

[10]  C. Dennis,et al.  The Association Between Antenatal Exposure to Selective Serotonin Reuptake Inhibitors and Autism: A Systematic Review and Meta-Analysis. , 2017, The Journal of clinical psychiatry.

[11]  Y. Kaplan,et al.  Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis. , 2016, Reproductive toxicology.

[12]  S. Ito,et al.  Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis. , 2016, Reproductive toxicology.

[13]  Sarah S. Mire,et al.  The Influence of Demographic Factors on the Identification of Autism Spectrum Disorder: A Review and Call for Research , 2015, Review Journal of Autism and Developmental Disorders.

[14]  Kenneth K C Man,et al.  Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies , 2015, Neuroscience & Biobehavioral Reviews.

[15]  J. N. van den Anker,et al.  Trends in pregnancy labeling and data quality for US-approved pharmaceuticals. , 2014, American journal of obstetrics and gynecology.

[16]  V. Smith,et al.  Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism , 2014, Archives of Disease in Childhood: Education & Practice Edition.

[17]  S. Gentile.  Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions , 2014, CNS Spectrums.

[18]  F. Rijsdijk,et al.  Genetic associations between the symptoms of attention-deficit/hyperactivity disorder and emotional lability in child and adolescent twins. , 2014, Journal of the American Academy of Child and Adolescent Psychiatry.

[19]  O. Spigset,et al.  Medication use in pregnancy: a cross-sectional, multinational web-based study , 2014, BMJ Open.

[20]  Mogens Vestergaard,et al.  Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. , 2013, JAMA.

[21]  J. Buitelaar,et al.  An inventory of European data sources for the long-term safety evaluation of methylphenidate , 2013, European Child & Adolescent Psychiatry.

[22]  C. Zaroff,et al.  Prevalence of autism spectrum disorders and influence of country of measurement and ethnicity , 2012, Social Psychiatry and Psychiatric Epidemiology.

[23]  K. Meador,et al.  Cognitive and neurodevelopmental effects of antiepileptic drugs , 2011, Epilepsy & Behavior.

[24]  M. Adam,et al.  Evolving knowledge of the teratogenicity of medications in human pregnancy , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[25]  Shekhar Saxena,et al.  Prevalence of intellectual disability: a meta-analysis of population-based studies. , 2011, Research in developmental disabilities.

[26]  A. Semczuk,et al.  Valproic acid transfer across human placental cotyledon during dual perfusion in vitro. , 2010, Annals of agricultural and environmental medicine : AAEM.

[27]  A. Coenen,et al.  Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate , 2009, Pharmacopsychiatry.

[28]  L. de Jong-van den Berg,et al.  Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. , 2006, BJOG : an international journal of obstetrics and gynaecology.

[29]  H. Koot,et al.  DSM-IV disorders in children with borderline to moderate intellectual disability. I: prevalence and impact. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  L. Altshuler,et al.  Placental passage of antidepressant medications. , 2003, The American journal of psychiatry.

[31]  Vicki A. Anderson,et al.  Development of Executive Functions Through Late Childhood and Adolescence in an Australian Sample , 2001, Developmental neuropsychology.

[32]  J. Gabrieli,et al.  Myelination and organization of the frontal white matter in children: a diffusion tensor MRI study. , 1999, Neuroreport.

[33]  E. Lammer,et al.  Neurobehavioral teratology of isotretinoin. , 1993, Reproductive toxicology.